论文部分内容阅读
目的 :观察国产注射用重组人尿激酶原 (rhPro-UK)治疗急性心肌梗死 (AMI)的效果和副作用。方法 :将31例发病 6h内的AMI患者随机分为rhPro -UK组 (n =16 )和尿激酶 (UK)组 (n =15 )。rhPro -UK组取rhPro -UK2 0mg溶于 10ml生理盐水中 3min内静脉注射 ,另取 2 0mg溶于 90ml生理盐水中 30min内静脉滴注完毕。尿激酶组取UK 15 0万单位溶于 10 0ml生理盐水中 30min内静脉滴注完毕。在溶栓 90min时进行选择性冠状动脉造影 ,评价梗死相关动脉开通情况。评价出血并发症以及生化指标变化情况。结果 :rhPro -UK组总的梗死相关动脉开通率为 74 .9% ,UK组为 6 6 .7% (P =0 .0 4 1)。rhPro -UK组无颅内出血 ,UK组有 1例致命性颅内出血 ;其余出血并发症以及生化指标变化情况 2组差异无统计学意义。结论 :AMI时应用国产rhPro -UK进行静脉溶栓成功率高 ,使用安全 ,副作用低
Objective: To observe the efficacy and side effects of domestic injection of recombinant human prourokinase (rhPro-UK) in the treatment of acute myocardial infarction (AMI). Methods: Thirty-one AMI patients were randomly divided into two groups: rhPro-UK group (n = 16) and urokinase group (n = 15). rhPro -UK group received rhPro -UK2 0mg dissolved in 10ml saline intravenously within 3min, another 20mg dissolved in 90ml saline intravenously within 30min. Urokinase group to take UK 15 0 units dissolved in 10 0ml normal saline within 30min intravenous infusion is completed. In the thrombolytic 90min selective coronary angiography, assessment of infarct-related artery opening situation. Evaluation of bleeding complications and biochemical changes. RESULTS: The total infarct-related artery opening rate was 74.9% in the rhPro-UK group and 6.6% (P = .041) in the UK group. There was no intracranial hemorrhage in rhPro-UK group and 1 fatal intracranial hemorrhage in UK group. There was no significant difference in the other bleeding complications and biochemical indexes between the two groups. Conclusion: AMI with domestic rhPro -UK intravenous thrombolysis success rate, safe, low side effects